Chinese Medicine Neuroaid Efficacy on Stroke Recovery: A Double-Blind, Placebo-Controlled, Randomized Study [Major Clinical Trial]

Conclusions— MLC601 is statistically no better than placebo in improving outcomes at 3 months when used among patients with acute ischemic stroke of intermediate severity. Longer treatment duration and follow-up of participants with treatment initiated after 48 hours may be considered in future studies. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00554723.

http://stroke.ahajournals.org/cgi/content/short/44/8/2093?rss=1

Source: Stroke - July 22, 2013 Category: Neurology Authors: Chen, C. L. H., Young, S. H. Y., Gan, H. H., Singh, R., Lao, A. Y., Baroque, A. C., Chang, H. M., Hiyadan, J. H. B., Chua, C. L., Advincula, J. M., Muengtaweepongsa, S., Chan, B. P. L., de Silva, H. A., Towanabut, S., Suwanwela, N. C., Poungvarin, N., Cha Tags: Acute Cerebral Infarction, Other Stroke Treatment - Medical Major Clinical Trial Source Type: research